Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Bausch Health Companies Inc.    BHC   CA0717341071


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Bausch Health : + Lomb Announces The European Launch Of LuxSmart And LuxGood Preloaded Intraocular Lenses

share with twitter share with LinkedIn share with facebook
05/28/2020 | 10:44am EDT

LAVAL - Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ('Bausch Health'), today announced the European launch of the company's first Extended Depth of Focus intraocular lens (IOL), LuxSmart, and a new monofocal IOL, LuxGood.

Both feature preloaded delivery systems and Pure Refractive Optics (PRO) Technology.

The LuxSmart and LuxGood IOLs utilize PRO technology, a design that is based only on refractive profiles and has no diffraction areas so patients are less likely to experience dysphotopsia.1,2 With the launch of this new platform, Bausch + Lomb now offers a complete range of innovative IOLs in Europe. Additionally, a toric version will become available later this year.

'LuxSmart and LuxGood feature an innovative premium optic design and PRO technology that reduces dysphotopsia, a common phenomenon that can occur in some premium IOLs and compromise a patient's vision,' said Thomas Appio, president, Bausch + Lomb/International. 'Bausch + Lomb will continue to focus its efforts on developing innovative products that meet the growing patient demand for premium cataract options.'

LuxSmart and LuxGood also feature a proprietary acrylic hydrophobic cross-linked copolymer material with an ultraviolet (UV) absorber that protects the eyes against damaging UV light. The platform is based on a 4-point fixation haptic design to achieve lens centration, rotational stability, posterior capsule opacification resistance3,4,5 and greater refractive predictability.6 The platform is available with and without violet light filtering.

Currently, more than 1.7 billion people in the world are afflicted with presbyopia, which typically begins around 40 to 45 years of age.7

About Bausch + Lomb

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words 'anticipates,' 'expects,' 'intends,' 'plans,' 'should,' 'could,' 'would,' 'may,' 'believes,' 'estimates,' 'potential,' 'target,' or 'continue' and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Company's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.


Arthur Shannon

Tel: (514) 856-3855

Email: arthur.shannon@bauschhealth.com

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
06/24BAUSCH HEALTH : Ortho dermatologics announces arazlo lotion, 0.045%, now availab..
06/24BAUSCH HEALTH COMPANIES INC : . - Ortho Dermatologics Launches ARAZLO Lotion, 0...
06/23BAUSCH HEALTH : Ortho Dermatologics Launches ARAZLO™ (tazarotene) Lotion, ..
06/18BAUSCH HEALTH : + LOMB ULTRA Silicone Hydrogel Contact Lenses Receive Approval i..
06/11BAUSCH HEALTH : Health Canada Issues Notice of Compliance for Bausch Health's DU..
06/09EXCLUSIVE : Chanel, Revlon, L'Oreal pivoting away from talc in some products
06/09EXCLUSIVE : Chanel, Revlon, L'Oreal pivoting away from talc in some products
06/05BAUSCH HEALTH : FDA Provides 510(k) Clearance For BAUSCH + LOMB INFUSE Daily Dis..
05/28BAUSCH HEALTH : + Lomb Announces The European Launch Of LuxSmart And LuxGood Pre..
05/26BAUSCH HEALTH COMPANIES INC. : Entry into a Material Definitive Agreement, Creat..
More news
Financials (USD)
Sales 2020 8 043 M - -
Net income 2020 -407 M - -
Net Debt 2020 22 174 M - -
P/E ratio 2020 -15,3x
Yield 2020 -
Capitalization 6 506 M 6 506 M -
EV / Sales 2019
EV / Sales 2020 3,57x
Nbr of Employees 21 700
Free-Float 99,4%
Duration : Period :
Bausch Health Companies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUSCH HEALTH COMPANIES IN
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 28,00 $
Last Close Price 18,34 $
Spread / Highest target 249%
Spread / Average Target 52,7%
Spread / Lowest Target -7,31%
EPS Revisions
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive Vice President
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
David Robert Hale Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-3.36%371 399
ROCHE HOLDING AG4.71%295 898
MERCK & CO., INC.-13.38%198 849
NOVARTIS AG-10.36%192 057
PFIZER, INC.-11.92%191 697